Key Highlights

  • Trading on November 19, 2026 pushed SELLAS Life Sciences (NASDAQ:SLS) down 13.98%, a day after a proposed USD 150.0 million offering that underwriters could extend by up to USD 22.5 million over 30 days.
  • PepGen (NASDAQ:PEPG) climbed 8.82% even though a USD 125 million Placement was struck on November 11, 2026 at USD 5.00 a share, a level the stock now sits roughly 16.8% beneath (calculated).
  • ARS Pharmaceuticals (NASDAQ:SPRY) declined 7.62% without an identified catalyst; its third-quarter net loss totaled USD 35.6 million, and cash is down roughly USD 107 million from the December 31, 2025 level (calculated).
  • Evolent Health (NYSE:EVH) lost 5.47%, as the third-quarter medical expense ratio moved from 85.0% up to 93.0%, pulling the adjusted EBITDA Margin down from 8.1% to 4.7%.

SELLAS Life Sciences (NASDAQ:SLS): Offering Lands Right After a Phase 3 Win

The biggest loser in the group had only just come off a notable clinical result. Its Phase 3 REGAL trial of galinpepimut-S, aimed at acute myeloid leukemia, reached its overall survival objective, as the company announced on November 17, 2026. Median survival reached 24.0 months, against 14.7 months for patients on the best available treatment in the control group. An underwritten offering worth USD 150.0 million came next, and banks hold an option to place as much as USD 22.5 million more over the following month. The company itself is the seller, with J.P. Morgan and TD Cowen running the sale under a shelf filing from March 20, 2026. Pricing was absent from the release, leaving the gap between the offer and the last trade unknown, and no use of proceeds was given. Underwriters tend to set such prices under the market to clear the block, a dynamic that typically weighs on shares. Measured against market value, the amount is around 4% (calculated, leaving out shares yet to be issued). The study was open-label with 126 patients, regulators could Demand more evidence, and the timing and terms of the raise carry no guarantee. Thin trading may amplify the swing.

PepGen (NASDAQ:PEPG): Gain Arrives Below the Offering Price

Among the four, PepGen (NASDAQ:PEPG) was the only riser, up 8.82%, though that still leaves it below the price investors paid in its latest raise. The company sold 25 million new shares at USD 5.00 apiece on November 11, 2026, aiming for gross proceeds of USD 125 million, one day after unveiling Phase 2 findings on PGN-EDODM1 in myotonic dystrophy type 1. In the 10 mg/kg arm, average splicing correction hit 46.5%, and no serious adverse events were logged. Company news in the days before this session was not found, so the advance lacks a confirmed trigger and could be a rebound. Cash of USD 104.8 million at September 30, 2026 would, with the gross proceeds, approach USD 229.8 million before fees (calculated). The third-quarter loss was USD 19.4 million. Chief among the risks is a partial clinical hold placed by the FDA in March 2026, which may also shape regulatory meeting timing. Shares issued dilute current holders, and low-priced stocks can reverse sharply. An option for up to 3.75 million extra shares sits with the underwriters, and the closing has not been verified. Guidance on a cash runway into 2028 existed before the raise, so the fresh funds mainly stretch the timeline for the next cohort.

ARS Pharmaceuticals (NASDAQ:SPRY): A Slow Drift Tied to Cash Burn

No company announcement, filing or analyst action from the recent period surfaced to explain the 7.62% slip, so no reason is put forward. The newest substantive material is the third-quarter report dated November 5, 2026. Revenue advanced to USD 37.7 million, up from USD 32.5 million a year ago. Net sales of neffy, the needle-free epinephrine spray, in the U.S. reached USD 33.4 million, a gain of roughly 6.7% (calculated). Management connected the difference against end-user demand, which expanded at a quicker pace, to swings in channel inventory. The net loss contracted to USD 35.6 million as selling expenses declined following the decision to stop broad consumer advertising. Cash plus short-term investments came to USD 138.4 million, down from roughly USD 245.0 million at the close of 2025. Management is aiming for cash-flow breakeven by year-end 2027. A single published report placed term-loan Debt around USD 121.8 million, a figure that rests on one source and remains unconfirmed here. The concern is funding: a delay against the breakeven aim would raise the odds of new capital, and sparse trading in a low-priced name can distort moves.

Evolent Health (NYSE:EVH): Costs Rise Faster Than Revenue

Evolent Health (NYSE:EVH) gave up 5.47%, the mildest slide in the set, and once more no company announcement accounting for the move turned up. The most recent verified item is the November 5, 2026 quarterly release. Sales climbed to USD 725.4 million from USD 479.5 million, whereas adjusted EBITDA went down, moving from USD 39.0 million to USD 34.3 million. The medical expense ratio, a gauge of medical costs paid under risk-based contracts relative to revenue, went from 85.0% to 93.0%. Full-year 2026 adjusted EBITDA guidance was lifted to USD 130.0 million to USD 135.0 million, while the USD 2.6 billion to USD 2.7 billion revenue range remained. Medical claims, not share sales, are the source of the strain. Net long-term debt stands at USD 969.5 million, and cash of USD 148.3 million covers part of it, leaving roughly USD 821.2 million net (calculated). Up to USD 50 million is slated for debt paydown by year-end. Seven renewals and fresh revenue deals this year improve visibility, yet contract wins need time to flow through to margins. Leverage, medical cost trends and how quickly wins translate into margin are the chief risks.

Where Things Stand

Capital raises explain two of the four moves, while cash burn and medical costs explain the other pair, so the split reflects different drivers rather than one theme. The sharpest fall, 13.98% at SELLAS Life Sciences (NASDAQ:SLS), follows its USD 150.0 million offering. PepGen (NASDAQ:PEPG) climbed 8.82% even though its placement was priced at USD 5.00 per share. ARS Pharmaceuticals (NASDAQ:SPRY) lacks an identified catalyst but carries cash burn, and Evolent Health (NYSE:EVH) also has no catalyst and faces margin pressure. Markers to watch include SELLAS pricing, the PepGen offering close and hold status, a first-quarter 2027 readout from ARS-2, plus the debt paydown and fourth-quarter report at Evolent. None of these guarantees a particular direction for the stocks.